Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Hefeng Pharmaceutical obtained approval from China's National Medical Products Administration for its lincomycin hydrochloride injection, according to a Friday filing with the Shanghai bourse.
The drug is indicated for streptococcus, pneumococcus, and staphylococcus infections in patients allergic to penicillin, the filing said.
Hospital purchases of the antibiotic reached 21.7 million yuan in 2025, according to market data cited in the filing.